Apicoplast ribosome

The apicoplast ribosome is a specialized 70S ribosome found within the apicoplast, a non-photosynthetic plastid organelle of apicomplexan parasites including Plasmodium (malaria) and Toxoplasma. The ribosome is of prokaryotic origin and is structurally distinct from cytosolic eukaryotic ribosomes, but it shows significant divergence and reduction in protein composition compared to bacterial and other organellar ribosomes. The apicoplast ribosome, comprising large (LSU) and small (SSU) subunits, is responsible for synthesizing proteins encoded in the apicoplast genome, many of which are essential for parasite survival, such as those involved in fatty acid and isoprenoid synthesis. The apicoplast ribosome is a clinically relevant therapeutic target because it is essential for parasite viability and sufficiently distinct from host cytoplasmic ribosomes to allow for selective inhibition by certain antibiotics (e.g., clindamycin, tetracycline). These drugs inhibit translation at the apicoplast ribosome, blocking production of critical enzymes and compromising organelle function, which leads to parasite death. There are, however, challenges to achieving drug specificity due to similarities with mitochondrial and bacterial ribosomes, potentially resulting in off-target effects. Apicoplast ribosome-targeting agents are an important class of antimalarials, especially for their “delayed death” phenotype, where inhibition results in failure to invade subsequent host cells rather than immediate cell lysis. No major issues or errors are apparent with the target designation. The apicoplast ribosome remains a validated and well-established target for the development of drugs against apicomplexan infections.

Inhibition of protein translation by binding the ribosome, blocking peptide synthesis in the apicoplast (and sometimes the mitochondrion); this leads to impaired production of essential metabolic enzymes and, eventually, parasite death